Antibacterial Drugs Market To Reach $44.13bn In 2020, A New Visiongain Study Predicts

10 September 2018
Pharma

A new report by visiongain forecasts the overall world market for human antibacterial treatments will reach $44.13bn in 2020. That revenue prediction and others appear in Antibacterial Drugs: World Industry and Market Prospects 2016-2026, published in March 2016.

This study also analyses qualitative issues affecting the antibacterial drug market from 2015, with recent events, opinions and predictions. Governmental incentives, clinical trial guidelines, treatment resistance, and many other forces are discussed. The result is a quantitative and qualitative analysis of the antibacterial industry and market, showing commercial potentials of those drugs from 2016 to 2026.

From 2015, new therapies and high medical needs encourage investments, developments, wider treatment and higher sales from bacteria-treating medicines. The new study discusses commercial potentials of human antibiotics and their producers. That investigation gives multilevel revenue forecasting to 2026. It shows predictions and discussions planners, organisers and leaders need. Visiongain is a business information publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials.
Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “The growth of the antibacterial drug market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market.
Current leading drugs will lose patent exclusivity from 2015 to 2026 thus opening opportunities for generics which will lead to a drop in market value. The uptake of new drugs launched within the second half of the forecast period however will stimulate that revenue growth. The overall antibacterial drug market is expected to grow with a CAGR of 2.5% from 2020-2026.”

That updated investigation shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It forecasts six antibiotic classes:

• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other medicines for treating bacterial infections.

Those analyses forecast the revenues of 43 leading antibacterial drugs from 2016 to 2026, including Zyvox, Cubicin, Augmentin, Zosyn/Tazocin, Avelox, Invanz and generic amoxicillin. The new survey also discusses antibacterial agents in clinical trials, examining research and development.

That report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU, Germany, France, the UK, Spain, Italy, Japan, Brazil, Russia, India, China and South Korea. That study also contains three interviews with other authorities on antimicrobial medicines.

Antibacterial Drugs: World Industry and Market Prospects 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Those studies analyse pharmaceuticals, medical devices, diagnostics and contract services, showing their technological, clinical and commercial potentials.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1